Avery Therapeutics

Avery Therapeutics is a company dedicated to advancing tissue-engineered therapies to treat diseases and injuries of human muscle. Avery's lead product, MyCardia™, is a tissue-engineered cardiac graft for treating heart failure, currently in the preclinical development stage. MyCardia™ is the world’s first off-the-shelf allogeneic tissue-engineered product designed to treat heart failure.Over 23 million people worldwide suffer from heart failure, which is the leading cause of morbidity and mortality in developed countries. In the United States, heart failure results in over $39 billion in annual treatment costs and more than 600,000 new cases of heart failure each year. The MyCardia™ Cardiac System has the potential to improve cardiac function and quality of life for patients with heart failure.